Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aβ1-6-CMVTT
- Development stage
- Preclinical
- Lead developer
- Saiba Biotech
- Modality
- Nanoparticles → Drug Delivery Systems, Peptides, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Aβ1-6-CMVTT is an experimental **active immunotherapy vaccine** for Alzheimer's disease that displays the N-terminal amyloid-beta epitope Aβ1-6 on a **cucumber mosaic virus-derived virus-like particle** containing a **tetanus toxoid universal T-helper epitope**. The design aims to induce a polyclonal anti-amyloid-beta antibody response against aggregated or deposited Aβ while minimizing autoreactive Aβ-specific T-cell activation by restricting the displayed self-antigen to the short Aβ1-6 B-cell epitope. In preclinical work, this CMVTT VLP platform generated strong and selective antibody responses, including in older mice, and sera recognized Alzheimer plaque material in brain sections. The program appears to be a preclinical or platform-stage vaccine concept associated with the CMVTT or CuMVTT VLP technology rather than a clinically established product.
- Other names
- Abeta1-6-CMVTTAbeta-1-6-CMVTTAbeta 1-6-CMVTTCMVTT-Aβ1-6CuMVTT-Aβ1-6
02
Targets
Aβ N-terminus (Amyloid beta peptide N-terminal epitope)
Beyond the preview
Go deeper on Aβ1-6-CMVTT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aβ1-6-CMVTT.